Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 776 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 509 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 641 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 762 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 405 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 318 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 378 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 460 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 4,720 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
ABCELLERA BIOLOGICS | 3,892 | -2,92 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
ANAVEX LIFE SCIENCES | 7,508 | -0,58 % | Anavex: H.C. Wainwright bestätigt Kaufempfehlung nach Alzheimer-Studiendaten | ||
VERACYTE | 27,000 | 0,00 % | S&P Dow Jones Indices: Veracyte Set to Join S&P SmallCap 600 | NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the... ► Artikel lesen | |
ASCLETIS PHARMA | 1,240 | +10,71 % | Sagimet Biosciences Inc.: Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567... ► Artikel lesen | |
BIOMEA FUSION | 1,955 | -3,46 % | Biomea Fusion, Inc.: Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate ... | ||
JASPER THERAPEUTICS | 2,330 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody... ► Artikel lesen | |
ABSCI | 2,550 | 0,00 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
LANTERN PHARMA | 3,920 | 0,00 % | Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints | ||
Y-MABS THERAPEUTICS | 8,610 | 0,00 % | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | ||
QIAGEN | 38,460 | +0,40 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
HILLEVAX | 2,090 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. | EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping... ► Artikel lesen | |
BIONTECH | 82,95 | -0,90 % | Evotec Aktie: Endlich Hoffnung? - BioNTech, Deutsche Bank, Deutsche Telekom, Deutz und RWE im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SCISPARC | 4,365 | 0,00 % | Morning Market Movers: SciSparc, HIND, SQFT, FGNX See Big Swings | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
EVOTEC | 6,214 | +1,04 % | Evotec-Aktie mit Kursverlusten (6,092 €) | Im deutschen Wertpapierhandel liegt die Evotec-Aktie gegenwärtig im Minus. Der jüngste Kurs betrug 6,09 Euro. Ein Preisabschlag in Höhe von 0,058 Euro müssen derzeit die Aktionäre von Evotec hinnehmen.... ► Artikel lesen |